Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea.
Sci Rep. 2021 Mar 19;11(1):6468. doi: 10.1038/s41598-021-86053-0.
Immunocompromised status can result in indeterminate QuantiFERON-TB Gold In-Tube (QFT-GIT) results, but the association of indeterminate results with immunocompetent status in children is unknown. Therefore, we aimed to identify factors associated with indeterminate QFT-GIT results for immunocompetent children. We conducted a retrospective chart review of children (aged ≤ 18 years) who underwent QFT-GIT between September 2006 and July 2017 at the Severance Hospital, Seoul, South Korea. Of the 2037 QFT-GIT assays included in the present study, 7.7% yielded indeterminate QFT-GIT results. Multivariable logistic regression analysis identified younger age (OR 0.88; 95% CI 0.836-0.927; P < 0.001), elevated white blood cell (WBC) count (OR 1.066; 95% CI 1.020-1.115; P = 0.005), decreased albumin levels (OR 0.505; 95% CI 0.316-0.807; P = 0.004), and low-dose steroid therapy (< 1 mg/kg per day of prednisone or equivalent for < 2 weeks) (OR 76.146; 95% CI 8.940-648.569; P < 0.001) as significant factors influencing indeterminate results. Younger age, high WBC count, low albumin levels, and low-dose steroid therapy were associated with indeterminate QFT-GIT results. Low-dose steroid therapy had the highest OR for the indeterminate results compared to other significant risk factors. Our study suggests that screening for steroid doses is important prior to performing interferon-gamma release assays for immunocompetent children.
免疫功能低下可导致不确定的 QuantiFERON-TB Gold In-Tube(QFT-GIT)结果,但免疫功能正常儿童的不确定结果与免疫功能低下的关系尚不清楚。因此,我们旨在确定与免疫功能正常儿童的不确定 QFT-GIT 结果相关的因素。我们对 2006 年 9 月至 2017 年 7 月在韩国首尔 Severance 医院接受 QFT-GIT 的儿童(年龄≤18 岁)进行了回顾性图表审查。在本研究中包含的 2037 项 QFT-GIT 检测中,7.7%的检测结果为不确定的 QFT-GIT。多变量逻辑回归分析确定年龄较小(OR 0.88;95%CI 0.836-0.927;P<0.001)、白细胞计数升高(OR 1.066;95%CI 1.020-1.115;P=0.005)、白蛋白水平降低(OR 0.505;95%CI 0.316-0.807;P=0.004)和低剂量类固醇治疗(<1mg/kg/天泼尼松或等效物治疗<2 周)(OR 76.146;95%CI 8.940-648.569;P<0.001)是影响不确定结果的重要因素。年龄较小、白细胞计数较高、白蛋白水平较低和低剂量类固醇治疗与不确定的 QFT-GIT 结果相关。与其他重要危险因素相比,低剂量类固醇治疗的不确定结果的 OR 最高。我们的研究表明,在为免疫功能正常的儿童进行干扰素γ释放试验之前,筛查类固醇剂量很重要。